

Head and Neck

Version Date:
March 8, 2024

Locally Advanced

Skin


VAR0259

Phase II/III
Adaptive
Randomized
Open-Label
Clinical Study to
Evaluate
Neoadjuvant &
Adjuvant V940
(mRNA-4157) in
Combination w/
Pembrolizumab
(MK-3475) vs
Standard of Care
& Pembrolizumab
Monotherapy in
Resectable
Locally Advanced
Cutaneous
Squamous Cell
Carcinoma

PI: Divi
Sponsor: Merck
Sharp & Dohme,
LLC

KEY


 Pending

 Open for Enrollment

 Observational Study

 Optional Path

[Link](#) Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy